GLP-1 Receptor Agonists and Cancer—The Promise Is Real - Takeaways - MDSpire

GLP-1 Receptor Agonists and Cancer—The Promise Is Real

  • By

  • Richard C. Wender

  • May 11, 2026

  • 0 min

Share

  • 1

    A study found that GLP-1 RA users with breast cancer had a 60% lower all-cause mortality compared to nonusers over 5 and 10 years.

  • 2

    GLP-1 RAs showed a significant relative increase in recurrence-free survival among users compared to nonusers and those on insulin or metformin.

  • 3

    No survival differences were observed between GLP-1 RA users and SGLT2 inhibitor users, although adjustments suggested potential benefits.

  • 4

    The study highlights the need for randomized clinical trials to explore the relationship between GLP-1 RAs and cancer outcomes.

  • 5

    Clinicians are advised to prescribe GLP-1 RAs for early-stage cancer patients, as they are generally safe and may improve outcomes.

Original Source(s)

GLP-1 Receptor Agonists and Cancer—The Promise Is Real

  • by Richard C. Wender

  • May 11, 2026

Related Content

Comparison of the diagnostic power of serum circulating miR-21, VEGF, and CA15-3 in breast cancer

Diagnosis and treatment of breast cancer metastasis to thyroid: a case report and literature review

25HC regulates the polarization of CD163+ macrophages in the immune microenvironment of triple-negative breast cancer through the interferon pathway